CClinicalTrials.gg
CompletedNCT03441750ChinaDPPUpdated Nov 15, 2021

Efficacy of Metformin in Preventing Diabetes in China

A Phase 4 interventional study of metformin and Standard lifestyle intervention in PreDiabetes, sponsored by Chinese Association of Geriatric Research. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-15.

Sponsored by Chinese Association of Geriatric Research · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
1,724
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A multicentred, randomized, open study to evaluate the efficacy of metformin in preventing Diabetes.

Read the detailed description

The increasing prevalence of prediabetes had been documented in the recent national surveillance in China. Prediabetes is an important risk factor for developing overt Diabetes and macro/micro vascular diseases. Pharmaceutical medications such as metformin had been proved effective in preventing Diabetes. Local studies are in need to guide the clinicians in their daily practice to prevent Diabetes in China. Therefore, China Diabetes Prevention Program(China DPP)is designed and conducted to compare the efficacy of metformin combined with lifestyle intervention versus lifestyle intervention alone in preventing Diabetes.

02

Conditions studied

  • PreDiabetes

Browse trials for

03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Diagnosis of IGR before the randomization based on the 1999 WHO diagnostic and classification criteria.
  2. Age: 18 ≤age≤70 years old.
  3. Not on a treatment of anti-diabetic agents, including Chinese traditional herbs lowering blood glucose for at least 6 months before screening.
  4. Male or non-pregnant, non-breastfeeding females, females without birthing plan in next three years.
  5. Body mass index (BMI) :21 kg/m2 ≤BMI\<32 kg/m2.
  6. Written informed consent given before any trial-related activities are carried out.

Main exclusion Criteria:

  1. Administration with medications for pre-existed diseases affect glucose metabolism (except thiazide diuretics when its daily dose≤12.5mg).
  2. Administration with anti-obesity agents (including Chinese traditional medicine) within 6 months of enrolment and during intervention.
  3. Administration with three or more than three types antihypertensive drugs.
  4. Diabetes patients (subjects with prior history of gestational Diabetes will not be excluded).
  5. Have any of the following cardiovascular conditions within 3 months prior to the screening visit: acute myocardial infarction, congestive heart failure defined as New York Heart Association class III/IV or left ventricular ejection fraction ≤40%,) or cerebrovascular accident.
  6. Persistent uncontrolled hypertension (systolic blood pressure ≥160mmHg, or diastolic blood pressure ≥100 mmHg).
  7. Impaired liver function, have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, ALT or AST levels ≥3 times the upper limit of the reference range at the screening visit.
  8. Renal dysfunction (eGFR\<45ml/min).
  9. Patients ventilated by ventilator.
  10. Hypersensitivity to metformin or to any of the excipients such as povidone K 30, magnesium stearate and hypromellose.
  11. Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic respiratory disease).
  12. Acute alcohol intoxication, alcoholism.
  13. Severe chronic gastrointestinal disease.
  14. Severe psychiatric illness.
  15. Cancer requiring treatment in past 5 years.
  16. Uncontrolled thyroid diseases.
  17. Women who are pregnant or breastfeeding .
  18. Participation in another clinical trial within the past 30 days .
  19. Other significant disease that in the Investigator's opinion would exclude the subject from the trial.
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,724 participants (actual)

Study arms

  • Experimental
    metformin plus standard lifestyle intervention

    Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.

    Drug: metformin

  • Other
    Standard lifestyle intervention

    Standard lifestyle advice will be united for all subjects by providing special booklet.

    Other: Standard lifestyle intervention

Interventions

  • Drugmetformin

    Metformin tablets will be administrated in the experimental arm.

    Also known as: Glucophage immediate release formulation

  • OtherStandard lifestyle intervention

    Standard lifestyle advice will be united for all subjects by providing special booklet. * All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes. * The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction. * Moderate intensity physical activity (150 minutes per week) is recommended. * Smoking cessation is encouraged for the smoker. * Excessive alcohol intake is encouraged to avoid.

05

What researchers measure

Primary outcomes

  1. Rate of newly diagnosed diabetes

    Time frame: The primary outcome will be evaluated when the last subject completes 2 years' intervention.

06

Study locations

1 site
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
07

References and documents

Publications

  • Ji L, Sun N, Zhang Y, Zhang L, Shen S, Wang X, Li Q, Dong L, Ren W, Qi L, Li Y, Yan S, Cheng W, Kuang H, Li G. Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study. Diabetes Obes Metab. 2020 Feb;22(2):158-166. doi: 10.1111/dom.13884. Epub 2019 Oct 24. PubMed 31512365 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03441750
Lead sponsor
Chinese Association of Geriatric Research
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Apr 25, 2017
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Nov 15, 2021

Study contacts

Guangwei Li, M.D., Ph.D.
principal investigator · Chinese Association of Geriatric Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion